THANK YOU FOR SUBSCRIBING
The round was driven by Spring Mountain Capital.
Vergent Bioscience, a cancer-focused biotechnology organization, reported today that it raised $8.7 million up in a Series A financing round drove by Spring Mountain Capital to subsidize its preclinical and clinical advancement exercises. Vergent is building up a tumor-targeted fluorescent research to help surgeons rapidly recognize and totally remove cancerous tissue during surgery.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
"Vergent is building up a truly necessary product for the surgical cancer market," said Raymond Wong, Managing Director and Head of the Growth Equity Group at Spring Mountain Capital. "Positive tumor edges are unfortunately normal in medical procedure today, and Vergent's innovation can possibly, especially enhance the way that cancer surgery is performed." is performed."
"We are excited to be partnering with Spring Mountain Capital," said John Santini, President, and CEO at Vergent. "Raymond and the group bring a wealth of resources to Vergent and this capital will help propel our tumor-focused on, fluorescent probe through early-clinical preliminaries." as per vcaonline.
See Also: SPARK Biopharma
More in News